Tercica: Growing Small
This article was originally published in Start Up
Executive SummaryArmed with a powerful, in-licensed late-stage molecule from Genentech, two-and-a half-year-old Tercica is about a year away from entering the eminently reachable market for treating short-stature children, a potentially significant segment of a $750 million annual US market. But unlike many start-up in-licensers that seek niche indications for their lead programs, Tercica won't be able to fly under the radar of the competition.
You may also be interested in...
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.